Skip to content

Squadron Capital Management LLC 13F Holdings · Q2 2026

Squadron Capital Management LLC reported 34 securities worth $322.25M in its SEC 13F filing for Q2 2026 (period ended 2026-06-30). Top holdings: RLMD (15.78%), CCCC (11.01%), COGT (10.39%). Among its top 25 positions this quarter: 10 new, 9 added, 4 trimmed.

RankTickerCompanyValue% PortfolioSharesAction
1RLMDRELMADA THERAPEUTICS INC$50.9M15.78%7.3MTrimmed
2CCCCC4 THERAPEUTICS INC$35.5M11.01%7.6MAdded
3COGTCOGENT BIOSCIENCES INC$33.5M10.39%865,000Added
4ZNTLZENTALIS PHARMACEUTICALS INC$20.0M6.21%4.1MAdded
5KODKODIAK SCIENCES INC$19.5M6.05%500,000Added
6RLAYRELAY THERAPEUTICS INC$18.1M5.63%970,000Added
7EWTXEDGEWISE THERAPEUTICS INC$11.8M3.66%290,000Trimmed
8MAZEMAZE THERAPEUTICS INC$10.0M3.10%335,000Added
9BIOABIOAGE LABS INC$9.9M3.08%405,000New
10IVAINVENTIVA SA$9.2M2.86%2.4MAdded
11ANLADLAI NORTYE LTD$8.8M2.73%764,876Trimmed
12CMPSCOMPASS PATHWAYS PLC$8.6M2.66%605,000New
13ELVNENLIVEN THERAPEUTICS INC$8.1M2.52%160,000New
14RZLTREZOLUTE INC$6.8M2.10%1.3MNew
15AVBPARRIVENT BIOPHARMA INC$6.4M1.97%183,000Added
16PALIPALISADE BIO INC$6.3M1.95%3.0MHold
17IKTINHIBIKASE THERAPEUTICS INC$6.1M1.89%3.0MTrimmed
18ADAGADAGENE INC$5.2M1.63%1.2MNew
19FBRXFORTE BIOSCIENCES INC$4.8M1.48%225,000New
20IFRXINFLARX NV$4.5M1.39%2.0MNew
21ASMBASSEMBLY BIOSCIENCES INC$4.4M1.36%160,000New
22PMNPROMIS NEUROSCIENCES INC$4.3M1.33%324,977Hold
23CTNMCONTINEUM THERAPEUTICS INC$4.3M1.32%260,000New
24DFTXDEFINIUM THERAPEUTICS INC$4.0M1.24%85,000New
25SLGLSOL-GEL TECHNOLOGIES LTD$3.9M1.20%52,000Added

Source: SEC Form 13F filings · as of 2026-06-30

Every position in this 13F-HR, with its change from the prior quarter.

13F holdings, latest quarter

SourceSEC EDGAR13F-HR